Sanbo Brain H1 net profit increased by more than 50% year-on-year, industry attention on expansion phase performance sustainability | Interpretations
①In the first half of this year, Sanbo Neurology achieved double growth in operating profit, mainly due to the expansion of the business scale and the increase in net income from acquiring companies; ② Sanbo Neurology is building two hospitals and plans to focus on the future expansion in the cni yangtze index and cni zhujiang index regions; ③ The industry is concerned about the sustainability of its expansion, the construction capabilities of the diagnostic and treatment team, and the relatively scarce professional talents in neurology.
shanghai microport endovascular medtech(group)co.,ltd. net profit increased by more than 44% in the first half of the year. Can going overseas alleviate the impact of Castor's price reduction?
1. Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. accelerates its 'going global' strategy, with overseas revenue increasing by 67.04% in the first half of the year, accounting for 8.84% of the total revenue; 2. The reporter from the 'Star Market Daily' asked employees of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. whether they would correspondingly adjust the prices facing dealers in response to the significant price reduction of Castor brackets' terminal. The other party refused to disclose more information, citing 'inconvenience to reply.'
Express News | Biomedical stocks in Hong Kong continued to rise in the afternoon, with Wuxi Bio up nearly 7%, Wuxi Apptec and Wuxi Huijian up more than 5%, Innocare and Beigene up more than 4%.
Lepu Medical Technology's performance continued to decline in the first half of the year. It is expected that the revenue of the formulated business will further decrease. | Interpretations
① lepu medical technology once again submitted a half-year report with a decline in performance, and the revenue of the company's three major business sectors decreased year-on-year. ② Due to reasons such as the aging of product pipelines, lepu medical technology determines that the revenue of the formulation business sector may decrease to around 1.5 billion-1.6 billion yuan. ③ The company conducted self-inspection and rectification in response to the issues and requirements raised in the administrative supervision and regulation measures decision issued by the Beijing Securities Regulatory Bureau.
The gross margin of solution injection products has declined, and the growth rate of imeik technology development's Q2 performance has dropped to single digits|speed reading announcement
imeik technology development H1 revenue and net income growth slowed down. Solution-based injection product gross margin has declined, and its proportion in total revenue further decreased. In addition to laying out the research and development pipeline for botulinum toxin, GLP-1 drugs, the company is also further expanding in the field of medical beauty equipment.
Continued high investment in R&D and advancing market expansion, Autobio Diagnostics' first-half revenue and net profit both doubled, according to the announcement.
①Autobio Diagnostics achieved growth in both H1 revenue and net profit, with the proportion of R&D expenses in total revenue continuously increasing. ②The revenue proportion of the company's reagent business did not increase as expected. ③The company plans to add actual production support for specific subfields in the content of the 'Expansion Project of In Vitro Diagnostic Product Capacity' project.